share_log

B of A Securities Maintains Buy on Lyra Therapeutics, Lowers Price Target to $11

Moomoo 24/7 ·  Mar 25 06:47

B of A Securities analyst Jason Gerberry maintains Lyra Therapeutics (NASDAQ:LYRA) with a Buy and lowers the price target from $12 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment